Thus, the on-target off-tumor activity of ISB 2001 was compared to a CD3 × CD38 TCE control and to the CD3 × BCMA TCEs teclistamab and alnuctamab in an HD peripheral blood mononuclear cell (PBMC) assay. The gene discussed is CD38; the disease is neoplasm.